nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.128	0.149	CbGbCtD
Dabrafenib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.102	0.118	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—ankylosing spondylitis	0.0881	0.103	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—ankylosing spondylitis	0.0513	0.0598	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0507	0.0591	CbGbCtD
Dabrafenib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0483	0.0564	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—ankylosing spondylitis	0.0474	0.0552	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—ankylosing spondylitis	0.0408	0.0475	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—ankylosing spondylitis	0.033	0.0385	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—ankylosing spondylitis	0.0314	0.0367	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—ankylosing spondylitis	0.031	0.0362	CbGbCtD
Dabrafenib—ABCB1—Prednisone—ankylosing spondylitis	0.0293	0.0342	CbGbCtD
Dabrafenib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.029	0.0338	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.027	0.0315	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.022	0.0256	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0188	0.022	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0186	0.0217	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0183	0.0213	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—ankylosing spondylitis	0.0176	0.0205	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—ankylosing spondylitis	0.0147	0.0171	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.011	0.0128	CbGbCtD
Dabrafenib—Dry skin—Betamethasone—ankylosing spondylitis	0.000511	0.00359	CcSEcCtD
Dabrafenib—Dry skin—Dexamethasone—ankylosing spondylitis	0.000511	0.00359	CcSEcCtD
Dabrafenib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.000508	0.00357	CcSEcCtD
Dabrafenib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.000508	0.00357	CcSEcCtD
Dabrafenib—Neoplasm—Methotrexate—ankylosing spondylitis	0.000506	0.00355	CcSEcCtD
Dabrafenib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000473	0.00332	CcSEcCtD
Dabrafenib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000473	0.00332	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisolone—ankylosing spondylitis	0.000465	0.00327	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000462	0.00325	CcSEcCtD
Dabrafenib—Epistaxis—Triamcinolone—ankylosing spondylitis	0.000447	0.00314	CcSEcCtD
Dabrafenib—Dry skin—Prednisone—ankylosing spondylitis	0.000445	0.00313	CcSEcCtD
Dabrafenib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000442	0.00311	CcSEcCtD
Dabrafenib—Renal failure acute—Methotrexate—ankylosing spondylitis	0.00044	0.00309	CcSEcCtD
Dabrafenib—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000435	0.00306	CcSEcCtD
Dabrafenib—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000435	0.00306	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000428	0.00301	CcSEcCtD
Dabrafenib—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.000427	0.003	CcSEcCtD
Dabrafenib—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000426	0.003	CcSEcCtD
Dabrafenib—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.000425	0.00299	CcSEcCtD
Dabrafenib—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000424	0.00298	CcSEcCtD
Dabrafenib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000417	0.00293	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000413	0.0029	CcSEcCtD
Dabrafenib—Pancreatitis—Prednisone—ankylosing spondylitis	0.000412	0.00289	CcSEcCtD
Dabrafenib—Erythema—Prednisolone—ankylosing spondylitis	0.000403	0.00283	CcSEcCtD
Dabrafenib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000396	0.00279	CcSEcCtD
Dabrafenib—Neutropenia—Prednisone—ankylosing spondylitis	0.000393	0.00276	CcSEcCtD
Dabrafenib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000388	0.00272	CcSEcCtD
Dabrafenib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000388	0.00272	CcSEcCtD
Dabrafenib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000386	0.00271	CcSEcCtD
Dabrafenib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000386	0.00271	CcSEcCtD
Dabrafenib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000385	0.0027	CcSEcCtD
Dabrafenib—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000383	0.00269	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000382	0.00269	CcSEcCtD
Dabrafenib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00038	0.00267	CcSEcCtD
Dabrafenib—Vision blurred—Prednisolone—ankylosing spondylitis	0.000379	0.00267	CcSEcCtD
Dabrafenib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000379	0.00266	CcSEcCtD
Dabrafenib—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000379	0.00266	CcSEcCtD
Dabrafenib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000372	0.00261	CcSEcCtD
Dabrafenib—Erythema—Triamcinolone—ankylosing spondylitis	0.00037	0.0026	CcSEcCtD
Dabrafenib—Erythema—Methylprednisolone—ankylosing spondylitis	0.000369	0.00259	CcSEcCtD
Dabrafenib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000369	0.00259	CcSEcCtD
Dabrafenib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000361	0.00253	CcSEcCtD
Dabrafenib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000361	0.00253	CcSEcCtD
Dabrafenib—Back pain—Triamcinolone—ankylosing spondylitis	0.000358	0.00252	CcSEcCtD
Dabrafenib—Angiopathy—Betamethasone—ankylosing spondylitis	0.00035	0.00246	CcSEcCtD
Dabrafenib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00035	0.00246	CcSEcCtD
Dabrafenib—Hypertension—Prednisolone—ankylosing spondylitis	0.000348	0.00244	CcSEcCtD
Dabrafenib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000345	0.00242	CcSEcCtD
Dabrafenib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000345	0.00242	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000344	0.00242	CcSEcCtD
Dabrafenib—Alopecia—Betamethasone—ankylosing spondylitis	0.000341	0.0024	CcSEcCtD
Dabrafenib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000341	0.0024	CcSEcCtD
Dabrafenib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000338	0.00237	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000336	0.00236	CcSEcCtD
Dabrafenib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000336	0.00236	CcSEcCtD
Dabrafenib—Erythema—Dexamethasone—ankylosing spondylitis	0.000336	0.00236	CcSEcCtD
Dabrafenib—Erythema—Betamethasone—ankylosing spondylitis	0.000336	0.00236	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00033	0.00232	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—ankylosing spondylitis	0.000329	0.00231	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000328	0.0023	CcSEcCtD
Dabrafenib—Cough—Triamcinolone—ankylosing spondylitis	0.000323	0.00227	CcSEcCtD
Dabrafenib—Hypertension—Triamcinolone—ankylosing spondylitis	0.00032	0.00225	CcSEcCtD
Dabrafenib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000319	0.00224	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000318	0.00223	CcSEcCtD
Dabrafenib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000315	0.00221	CcSEcCtD
Dabrafenib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000314	0.00221	CcSEcCtD
Dabrafenib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000314	0.00221	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—ankylosing spondylitis	0.000314	0.00221	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—ankylosing spondylitis	0.000313	0.0022	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000313	0.0022	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000312	0.00219	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000308	0.00217	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—ankylosing spondylitis	0.000307	0.00216	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000305	0.00214	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—ankylosing spondylitis	0.000305	0.00214	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—ankylosing spondylitis	0.000303	0.00213	CcSEcCtD
Dabrafenib—Oedema—Triamcinolone—ankylosing spondylitis	0.000302	0.00212	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—ankylosing spondylitis	0.0003	0.00211	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—ankylosing spondylitis	0.0003	0.00211	CcSEcCtD
Dabrafenib—Infection—Methylprednisolone—ankylosing spondylitis	0.000299	0.0021	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—ankylosing spondylitis	0.000298	0.0021	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—ankylosing spondylitis	0.000297	0.00209	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—ankylosing spondylitis	0.000297	0.00209	CcSEcCtD
Dabrafenib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000296	0.00208	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000295	0.00207	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—ankylosing spondylitis	0.000294	0.00207	CcSEcCtD
Dabrafenib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000293	0.00206	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—ankylosing spondylitis	0.000292	0.00206	CcSEcCtD
Dabrafenib—Erythema—Prednisone—ankylosing spondylitis	0.000292	0.00206	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000292	0.00205	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000291	0.00205	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—ankylosing spondylitis	0.00029	0.00204	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—ankylosing spondylitis	0.00029	0.00204	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000286	0.00201	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—ankylosing spondylitis	0.000286	0.00201	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000282	0.00198	CcSEcCtD
Dabrafenib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000282	0.00198	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000281	0.00197	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000277	0.00195	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—ankylosing spondylitis	0.000276	0.00194	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000275	0.00193	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000275	0.00193	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000275	0.00193	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—ankylosing spondylitis	0.000274	0.00193	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—ankylosing spondylitis	0.000274	0.00193	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000273	0.00192	CcSEcCtD
Dabrafenib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000273	0.00192	CcSEcCtD
Dabrafenib—Infection—Betamethasone—ankylosing spondylitis	0.000272	0.00191	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—ankylosing spondylitis	0.000272	0.00191	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—ankylosing spondylitis	0.00027	0.0019	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000269	0.00189	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000269	0.00189	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000268	0.00189	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000268	0.00189	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000265	0.00186	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000265	0.00186	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000262	0.00184	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—ankylosing spondylitis	0.00026	0.00183	CcSEcCtD
Dabrafenib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00026	0.00183	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000256	0.0018	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—ankylosing spondylitis	0.000256	0.0018	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000255	0.00179	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000254	0.00178	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000253	0.00178	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—ankylosing spondylitis	0.000253	0.00177	CcSEcCtD
Dabrafenib—Chills—Methotrexate—ankylosing spondylitis	0.000252	0.00177	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00025	0.00175	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00025	0.00175	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—ankylosing spondylitis	0.000249	0.00175	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—ankylosing spondylitis	0.000249	0.00175	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—ankylosing spondylitis	0.000248	0.00174	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000248	0.00174	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—ankylosing spondylitis	0.000248	0.00174	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000247	0.00174	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000246	0.00173	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000246	0.00173	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000244	0.00172	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—ankylosing spondylitis	0.000244	0.00172	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000242	0.0017	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000239	0.00168	CcSEcCtD
Dabrafenib—Oedema—Prednisone—ankylosing spondylitis	0.000239	0.00168	CcSEcCtD
Dabrafenib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000238	0.00167	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000238	0.00167	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000238	0.00167	CcSEcCtD
Dabrafenib—Infection—Prednisone—ankylosing spondylitis	0.000237	0.00167	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000237	0.00166	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000237	0.00166	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—ankylosing spondylitis	0.000236	0.00166	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000236	0.00166	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—ankylosing spondylitis	0.000236	0.00166	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000234	0.00164	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—ankylosing spondylitis	0.000232	0.00163	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000231	0.00162	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—ankylosing spondylitis	0.00023	0.00162	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—ankylosing spondylitis	0.000226	0.00159	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000224	0.00157	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000224	0.00157	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000223	0.00156	CcSEcCtD
Dabrafenib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000222	0.00156	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000219	0.00154	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000217	0.00153	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—ankylosing spondylitis	0.000217	0.00153	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000217	0.00152	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000217	0.00152	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000217	0.00152	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000217	0.00152	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000217	0.00152	CcSEcCtD
Dabrafenib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000216	0.00152	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—ankylosing spondylitis	0.000216	0.00152	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000214	0.0015	CcSEcCtD
Dabrafenib—Cough—Methotrexate—ankylosing spondylitis	0.000213	0.0015	CcSEcCtD
Dabrafenib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000213	0.0015	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000208	0.00146	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—ankylosing spondylitis	0.000208	0.00146	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000208	0.00146	CcSEcCtD
Dabrafenib—Rash—Prednisolone—ankylosing spondylitis	0.000207	0.00146	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000207	0.00145	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000207	0.00145	CcSEcCtD
Dabrafenib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000206	0.00145	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—ankylosing spondylitis	0.000206	0.00145	CcSEcCtD
Dabrafenib—Headache—Prednisolone—ankylosing spondylitis	0.000206	0.00145	CcSEcCtD
Dabrafenib—Constipation—Prednisone—ankylosing spondylitis	0.000204	0.00143	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—ankylosing spondylitis	0.0002	0.0014	CcSEcCtD
Dabrafenib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000199	0.0014	CcSEcCtD
Dabrafenib—Infection—Methotrexate—ankylosing spondylitis	0.000198	0.00139	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—ankylosing spondylitis	0.000197	0.00138	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000197	0.00138	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000196	0.00137	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000195	0.00137	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000195	0.00137	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—ankylosing spondylitis	0.000195	0.00137	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000194	0.00136	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—ankylosing spondylitis	0.000194	0.00136	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000194	0.00136	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000193	0.00136	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000192	0.00135	CcSEcCtD
Dabrafenib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000192	0.00135	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—ankylosing spondylitis	0.00019	0.00134	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00019	0.00134	CcSEcCtD
Dabrafenib—Rash—Methylprednisolone—ankylosing spondylitis	0.00019	0.00134	CcSEcCtD
Dabrafenib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00019	0.00133	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—ankylosing spondylitis	0.000189	0.00133	CcSEcCtD
Dabrafenib—Headache—Methylprednisolone—ankylosing spondylitis	0.000189	0.00133	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000189	0.00133	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000189	0.00133	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000188	0.00132	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000188	0.00132	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—ankylosing spondylitis	0.000186	0.00131	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000182	0.00128	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—ankylosing spondylitis	0.000181	0.00127	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000181	0.00127	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—ankylosing spondylitis	0.00018	0.00127	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—ankylosing spondylitis	0.000179	0.00126	CcSEcCtD
Dabrafenib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000179	0.00126	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000176	0.00124	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—ankylosing spondylitis	0.000174	0.00122	CcSEcCtD
Dabrafenib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000174	0.00122	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000173	0.00122	CcSEcCtD
Dabrafenib—Rash—Betamethasone—ankylosing spondylitis	0.000173	0.00121	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—ankylosing spondylitis	0.000173	0.00121	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000173	0.00121	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000173	0.00121	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000172	0.00121	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—ankylosing spondylitis	0.000172	0.00121	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—ankylosing spondylitis	0.000172	0.00121	CcSEcCtD
Dabrafenib—Headache—Betamethasone—ankylosing spondylitis	0.000172	0.00121	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—ankylosing spondylitis	0.000171	0.0012	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—ankylosing spondylitis	0.000169	0.00119	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000163	0.00115	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000163	0.00115	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—ankylosing spondylitis	0.000163	0.00114	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—ankylosing spondylitis	0.000163	0.00114	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—ankylosing spondylitis	0.000158	0.00111	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000158	0.00111	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000158	0.00111	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—ankylosing spondylitis	0.000152	0.00107	CcSEcCtD
Dabrafenib—Rash—Prednisone—ankylosing spondylitis	0.000151	0.00106	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—ankylosing spondylitis	0.00015	0.00106	CcSEcCtD
Dabrafenib—Headache—Prednisone—ankylosing spondylitis	0.00015	0.00105	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000147	0.00103	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—ankylosing spondylitis	0.000143	0.00101	CcSEcCtD
Dabrafenib—Nausea—Prednisone—ankylosing spondylitis	0.000142	0.000996	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—ankylosing spondylitis	0.000141	0.000992	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000137	0.000959	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—ankylosing spondylitis	0.000132	0.000927	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—ankylosing spondylitis	0.000127	0.000891	CcSEcCtD
Dabrafenib—Rash—Methotrexate—ankylosing spondylitis	0.000126	0.000884	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000126	0.000883	CcSEcCtD
Dabrafenib—Headache—Methotrexate—ankylosing spondylitis	0.000125	0.000878	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—ankylosing spondylitis	0.000119	0.000833	CcSEcCtD
